Polymorphisms in the CYP19 gene that influence bone mineral density

Pharmacogenomics

Volumn 8, Issue 4, 2007, Pages 339-352

  Riancho, José A ^a  

^a UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Aromatase; CYP19A1; Differential allelic expression; Estrogen; Estrogen receptors; Fractures; Osteoporosis; Polymorphisms

Indexed keywords

ANDROGEN; AROMATASE; ESTROGEN;

AROMATIZATION; BONE DENSITY; BONE MASS; ENZYME ACTIVITY; ESTROGEN ACTIVITY; ESTROGEN SYNTHESIS; FRAGILITY FRACTURE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HOMEOSTASIS; HUMAN; OSTEOPOROSIS; POSTMENOPAUSE; PREVALENCE; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; AROMATASE; BONE AND BONES; BONE DENSITY; HOMEOSTASIS; HUMANS; OSTEOPOROSIS; POLYMORPHISM, GENETIC; VARIATION (GENETICS);

EID: 34247129195     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.4.339     Document Type: Review

References (91)

1. Melton LJ: How many women have osteoporosis now? J. Bone Miner. Res. 10, 175-177 (1995).
2. Ammann P, Rizzoli R: Bone strength and its determinants. Osteoporos. Int. 14(Suppl. 3), S13-S18 (2003).
3. Simpson ER, Mahendroo MS, Means GD et al.: Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr. Rev. 15, 342-355 (1994).
4. Watanabe M, Simpson ER, Pathirage N, Nakajin S, Clyne CD: Aromatase expression in the human fetal osteoblastic cell line SV-HFO. J. Mol. Endocrinol. 32, 533-545 (2004).
5. Riggs BL, Khosla S, Melton LJ: Sex steroids and the construction and conservation of adult skeleton. Endocr. Rev. 23, 279-302 (2002).
6. Simpson ER, Davis SR: Aromatase and the regulation of estrogen biosynthesis - some new perspectives. Endocrinology 142, 4589-4594 (2001).
7. Smith IE, Dowsett M: Aromatase inhibitors in breast cancer. N. Engl. J. Med. 348, 2431-2442 (2003).
8. Compston J: Local biosynthesis of sex steroids in bone. J. Clin. Endocrinol. Metab. 87, 5398-5400 (2002).
9. Herynk MH, Fuqua SAW: Estrogen receptor mutations in human disease. Endocr. Rev. 25, 869-898 (2004).
10. Simoncini T, Genazzani AR: Non-genomic actions of sex steroid hormones. Eur. J. Endocrinol. 148, 281-292 (2003).
11. Turner RT, Riggs BL, Spelsberg TC: Skeletal effects of estrogen. Endocr. Rev. 15, 275-300 (1994).
12. Khosla S, Melton LJ, Riggs BL: Estrogen and the male skeleton. J. Clin. Endocrinol. Metab. 87, 1443-1450 (2002).
13. Ross FP: Interleukin 7 and estrogen-induced bone loss. Trends Endocrinol. Metab. 14, 147-149 (2003).
14. Syed FS, Khosla S: Mechanisms of sex steroid effects on bone. Biochem. Biophys. Res. Commun. 328, 688-696 (2005).
15. Grumbach MM, Auchus RJ: Estrogen: consequences and implications of human mutations in synthesis and action. J. Clin. Endocrinol. Metab. 84, 4677-4694 (1999).
16. Herrmann BL, Saller B, Janssen OE et al.: Impact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 gene. J. Clin. Endocrinol. Metab. 87, 5476-5484 (2002).
17. Bilezikian JP, Morishima A, Bell J, Grumbach MM: Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. J. Clin. Endocrinol. Metab. 339, 599-603 (1998).
18. Gennari L, Nuti R, Bilezikian JP: Aromatase activity and bone homeostasis in men. J. Clin. Endocrinol. Metab. 89, 5898-5907 (2004).
19. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr. Rev. 23, 570-578 (2002).
20. Michaelsson K, Baron JA, Farahmand BY et al.: Hormone replacement therapy and risk of hip fracture: population based case-control study. Br. Med. J. 316, 1858-1863 (1998).
21. Torgerson DJ, Bell-Syer SE: Hormone replacement therapy and prevention of nonvertebral fractures. A meta-analysis of randomized trials. JAMA 285, 2891-2897 (2001).
22. Gennari L, Merlotti D, Martini G et al.: Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly men. J. Clin. Endocrinol. Metab. 88, 5327-5333 (2003).
23. Khosla S, Melton LJ, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL: Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J. Clin. Endocrinol. Metab. 83, 2266-2274 (1998).
24. Miyaura C, Toda K, Inada M et al.: Sex- and age-related response to aromatase deficiency in bone. Biochem. Biophys. Res. Commun. 280, 1062-1068 (2001).
25. McCloskey E: Effects of third-generation aromatase inhibitors on bone. Eur. J. Cancer 42, 1044-1051 (2006).
26. Lester J, Coleman R: Bone loss and the aromatase inhibitors. Br. J. Cancer 93(Suppl. 1), S16-S22 (2005).
27. Taxel P, Kennedy DG, Fall PM, Willard AK, Clive JM, Raisz LG: The effect of aromatase inhibition on sex steroids, gonadotropins, and markers of bone turnover in older men. J. Clin. Endocrinol. Metab. 86, 2869-2874 (2001).
28. Leder BZ, le Blanc K, Schoenfeld DA, Eastell R, Finkelstein JS: Differential effects of androgens and estrogens on bone turnover in normal men. J. Clin. Endocrinol. Metab. 88, 204-210 (2003).
29. Falahati-Nini A, Riggs BL, Atkinson EJ, O'Fallon M, Estell R, Khosla S: Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J. Clin. Invest. 106, 1533-1560 (2000).
30. Harada N, Utsumi T, Takagi Y: Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons in carcinogenesis. Proc. Natl Acad. Sci. USA 90, 11312-11316 (1993).
31. Toda K, Terashima M, Mitsuuchi Y et al.: Alternative usage of different poly(A) addition signals for two major species of mRNA encoding human aromatase P-450. FEBS Lett. 247, 371-376 (1989).
32. Shozu M, Zhao Y, Bulun SE, Simpson ER: Multiple splicing events involved in regulation of human aromatase expression by a novel promoter, I.6. Endocrinology 139, 1610-1617 (1998).
33. Simpson ER: Role of aromatase in sex steroid action. J. Mol. Endocrinol. 25, 1549-1556 (2000).
34. Mendelson CR, Jiang B, Shelton JM, Richardson JA, Hinshelwood MM: Transcriptional regulation of aromatase in placenta and ovary. J. Steroid Biochem. Mol. Biol. 95, 25-33 (2005).
35. Sebastian S, Takayama K, Shozu M, Bulun SE: Cloning and characterization of a novel endothelial promoter of the human CYP19 (aromatase P450) gene that is up-regulated in breast cancer tissue. Mol. Endocrinol. 16, 2243-2254 (2002).
36. Enjuanes A, Garcia-Giralt N, Supervia A et al.: A new SNP in a negative regulatory region of the CYP19A1 gene is associated with lumbar spine BMD in postmenopausal women. Bone 38, 738-743 (2006).
37. Bulun SE, Sebastian S, Takayama K, Suzuki T, Sasano H, Shozu M: The human CYP19 (aromatase P450) gene: update on physiologic roles and genomic organization of promoters. J. Steroid Biochem. Mol. Biol. 86, 219-224 (2003).
38. Enjuanes A, Garcia-Giralt N, Surks MI et al.: Regulation of CYP19 gene expression in primary human osteoblasts: effects of vitamin D and other treatments. Eur. J. Endocrinol. 148, 519-526 (2003).
39. Shozu M, Simpson ER: Aromatase expression of human osteoblast-like cells. Moll. Cell. Endocrinol. 139, 117-129 (1998).
40. Tanaka S, Haji M, Takayanagi R, Tanaka S, Sugioka Y, Nawata H: 1,25-Dihydroxyvitamin D3 enhances the enzymatic activity and expression of the messenger ribonucleic acid for aromatase cytochrome P450 synergistically with dexamethasone depending on the vitamin D receptor level in cultured human osteoblasts. Endocrinology 137, 1860-1869 (1996).
41. Yanase T, Suzuki S, Goto K et al.: Aromatase in bone: roles of Vitamin D3 and androgens. J. Steroid Biochem. Mol. Biol. 86, 393-397 (2003).
42. Fiorelli G, Frediani U, Martineti V et al.: Aromatase expression and activity in the human leukaemic cell line FLG 29.1. J. Steroid Biochem. Mol. Biol. 66, 105-112 (1998).
43. McTernan PG, Anderson LA, Anwar AJ et al.: Glucocorticoid regulation of p450 aromatase activity in human adipose tissue: gender and site differences. J. Clin. Endocrinol. Metab. 87, 1327-1336 (2002).
44. Dieudonne MN, Sammari A, Dos SE, Leneveu MC, Giudicelli Y, Pecquery R: Sex steroids and leptin regulate 11β-hydroxysteroid dehydrogenase I and P450 aromatase expressions in human preadipocytes: sex specificities. J. Steroid Biochem. Mol. Biol. 99, 189-196 (2006).
45. Zhao Y, Nichols JE, Bulun SE, Mendelson CR, Simpson ER: Aromatase P450 gene expression in human adipose tissue. Role of a Jak/STAT pathway in regulation of the adipose-specific promoter. J. Biol. Chem. 270, 16449-16457 (1995).
46. Clyne CD, Kovacic A, Speed CJ, Zhou J, Pezzi V, Simpson ER: Regulation of aromatase expression by the nuclear receptor LRH-1 in adipose tissue. Mol. Cell. Endocrinol. 215, 39-44 (2004).
47. Kendall A, Dowsett M: Novel concepts for the chemoprevention of breast cancer through aromatase inhibition. Endocr. Relat. Cancer 13, 827-837 (2006).
48. Su B, Diaz-Cruz ES, Landini S, Brueggemeier RW: Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition. J. Med. Chem. 49, 1413-1419 (2006).
49. Diaz-Cruz ES, Shapiro CL, Brueggemeier RW: Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J. Clin. Endocrinol. Metab. 90, 2563-2570 (2005).
50. Simpson ER, Misso M, Hewitt KN et al.: Estrogen - the good, the bad, and the unexpected. Endocr. Rev. 26, 322-330 (2005).
51. Ralston SH: Genetic control of susceptibility to osteoporosis. J. Clin. Endocrinol. Metab. 87, 2460-2466 (2002).
52. Peacock M, Turner CH, Econs MJ, Foroud T: Genetics of osteoporosis. Endocr. Rev. 23, 303-326 (2002).
53. Michaelsson K, Melhus H, Ferm H, Ahlbom A, Pedersen NL: Genetic liability to fractures in the elderly. Arch. Intern. Med. 165, 1825-1830 (2005).
54. Zarrabeitia A, Zarrabeitia MT, Valero C, González-Macias J, Riancho JA: Age-related influence of common aromatase gene polymorphisms on bone mass of healthy men. Bone 35, 243-248 (2004).
55. Dick IM, Devine A, Prince RL: Association of an aromatase TTTA repeat polymorphism with circulating estrogen, bone structure, and biochemistry in older women. Am. J. Physiol. Endocrinol. Metab. 288, E989-E995 (2005).
56. Salmen T, Heikkinen AM, Mahonen A et al.: Relation of androgen receptor gene polymorphism to bone mineral density and fracture risk in early postmenopausal women during a 5-year randomized hormone replacement therapy trial. J. Bone Miner. Res. 18, 319-324 (2003).
57. Tofteng CL, Kindmark A, Brandstrom H et al.: Polymorphisms in the CYP19 and AR genes-relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy: The Danish Osteoporosis Prevention Study. Calcif. Tissue Int. 74, 25-34 (2004).
58. Moron FJ, Mendoza N, Vazquez F et al.: Multilocus analysis of estrogen-related genes in Spanish postmenopausal women suggests an interactive role of ESR1, ESR2 and NRIP1 genes in the pathogenesis of osteoporosis. Bone 39, 213-221 (2006).
59. Zmuda JM, Cauley JA, Danielson ME, Ferrell RE: Vitamin D receptor and aromatase gene interaction and bone mass in older African-American women. Metabolism 52, 521-523 (2003).
60. Mendoza N, Moron FJ, Vazquez F et al.: Weighting the effect of CYP19A gene in bone mineral density of postmenopausal women. Bone 38, 951-953 (2006).
61. Riancho JA, Zarrabeitia MT, Valero C et al.: Aromatase gene and osteoporosis: relationship of ten polymorphic loci with bone mineral density. Bone 36, 917-925 (2005).
62. Valero C, Zarrabeitia MT, Hernandez JL, Zarrabeitia MT, González-Macías J, Riancho JA: Bone mass in young adults: relationship with gender, weight, and genetic factors. J. Intern. Med. 258, 554-562 (2005).
63. Zarrabeitia MT, Hernandez JL, Valero C et al.: A common polymorphism in the 5′-untranslated region of the aromatase gene influences bone mass and fracture risk. Eur. J. Endocrinol. 150, 699-704 (2004).
64. Labrie F, Belanger A, Cusan L, Gomez JL, Candas B: Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J. Clin. Endocrinol. Metab. 82, 2396-2402 (1997).
65. Gennari L, Masi L, Merlotti D et al.: A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism. J. Clin. Endocrinol. Metab. 89, 2803-2810 (2004).
66. van Pottelbergh I, Goemaere S, Kaufman JM: Bioavailable estradiol and an aromatase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age. J. Clin. Endocrinol. Metab. 88, 3075-3081 (2003).
67. Lorentzon M, Swanson C, Eriksson AL, Mellstrom D, Ohlsson C: Polymorphisms in the aromatase gene predict areal BMD as a result of affected cortical bone size: the GOOD study. J. Bone Miner. Res. 21, 332-339 (2006).
68. Tworoger SS, Chubak J, Aiello EJ et al.: Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. Cancer Epidemiol. Biomarkers Prev. 13, 94-101 (2004).
69. Dunning AM, Dowsett M, Healey CS et al.: Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J. Natl Cancer Inst. 96, 936-945 (2004).
70. Somner J, McLellan S, Cheung J et al.: Polymorphisms in the P450 c17(17-hydroxylase/17,20-lyase) and P450 c19 (aromatase) genes: association with serum sex steroid concentrations and bone mineral density in postmenopausal women. J. Clin. Endocrinol. Metab. 89, 344-351 (2004).
71. Remes T, Vaisanen SB, Mahone A et al.: Aerobic exercise and bone mineral density in middle-aged Finish men: a controlled randomized trial with reference to androgen receptor, aromatase, and estrogen receptor-α gene polymorphisms. Bone 32, 412-420 (2003).
72. Yang TL, Xiong DH, Guo Y, Recker RR, Deng HW: Association analyses of CYP19 gene polymorphisms with height variation in a large sample of Caucasian nuclear families. Hum. Genet. 120, 119-125 (2006).
73. Ellis JA, Stebbing M, Harrap SB: Significant population variation in adult male height associated with the Y chromosome and the aromatase gene. J. Clin. Endocrinol. Metab. 86, 4147-4150 (2001).
74. Weedon MN, Turner M, Knight B, Clark P, Hattersley AT, Frayling TM: Variants in the aromatase gene and on the Y-chromosome are not associated with adult height or insulin resistance in a UK population. Clin. Endocrinol. (Oxf.) 59, 175-179 (2003).
75. Long JR, Shu XO, Cai Q et al.: CYP19A1 genetic polymorphisms may be associated with obesity-related phenotypes in Chinese women. Int. J. Obes. (Lond.) 31(3), 418-423 (2007).
76. Tworoger SS, Chubak J, Aiello EJ et al.: The effect of CYP19 and COMT polymorphisms on exercise-induced fat loss in postmenopausal women. Obes. Res. 12, 972-981 (2004).
77. Reid IR: Relationships among body mass, its components, and bone. Bone 31, 547-555 (2002).
78. Ronti T, Lupattelli G, Mannarino E: The endocrine function of adipose tissue: an update. Clin. Endocrinol. (Oxf.) 64, 355-365 (2006).
79. Blain H, Vuillemin A, Guillemin F et al.: Serum leptin level is a predictor of bone mineral density in postmenopausal women. J. Clin. Endocrinol. Metab. 87, 1030-1035 (2002).
80. Haberland M, Schilling AF, Rueger JM, Amling M: Brain and bone: central regulation of bone mass. J. Bone Joint Surg. 83A, 1871-1876 (2001).
81. Hamrick MW: Leptin, bone mass, and the thrifty phenotype. J. Bone Miner. Res. 19, 1607-1611 (2004).
82. Riancho JA: Weighting the effect of CYP19A gene in bone mineral density of postmenopausal women. Bone 38, 951-953 (2006).
83. Guo Y, Xiong DH, Yang TL, Guo YF, Recker RR, Deng HW: Polymorphisms of estrogen-biosynthesis genes CYP17 and CYP19 may influence age at menarche: a genetic association study in Caucasian females. Hum. Mol. Genet. 15, 2401-2408 (2006).
84. Kristensen VN, Harada N, Yoshimura N, Haraldsen E, Lonning PE, Erikstein B et al.: Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene 19, 1329-1333 (2000).
85. Riancho JA, Valero C, Naranjo A, Morales DJ, Sanudo C, Zarrabeitia MT: Identification of an aromatase haplotype that is associated with gene expression and postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 92, 660-665 (2007).
86. Stewart TL, Jin H, McGuigan FE et al.: Haplotypes defined by promoter and intron 1 polymorphisms of the COLIA1 gene regulate bone mineral density in women. J. Clin. Endocrinol. Metab. 91, 3575-3583 (2006).
87. van Meurs JB, Rivadeneira F, Jhamai M et al.: Common genetic variation of the low-density lipoprotein receptor-related protein 5 and 6 genes determines fracture risk in elderly white men. J. Bone Miner. Res. 21, 141-150 (2006).
88. Riancho JA, Zarrabeitia MT, Valero C, Sanudo C, Mijares V, Gonzalez-Macias J: A gene-to-gene interaction between aromatase and estrogen receptors influences bone mineral density. Eur. J. Endocrinol. 155, 53-59 (2006).
89. Masi L, Becherini L, Gennari L et al.: Polymorphism of the aromatase gene in postmenopausal italian women: distribution and correlation with bone mass and fracture risk. J. Clin. Endocrinol. Metab. 86, 2263.2269 (2001).
90. Sowers MR, Wilson AL, Kardia SR, Chu J, Ferrell R: Aromatase gene (CYP19) polymorphisms and endogenous androgen concentrations in a multiracial/multiethnic, multisite study of women at midlife. Am. J. Med. 119(Suppl. 1), S23-S30 (2006).
91. Xiong DH, Zhao LJ, Xiao P et al.: Robust and comprehensive analysis of 20 osteoporosis candidate genes by very high-density single-nucleotide polymorphism screen among 405 white nuclear families identified significant association and gene.gene interaction. J. Bone Miner. Res. 21, 1678-1695 (2006).